Abstract Library

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,

#4335 Late nephrotoxicity of peptide receptor radionuclide therapy (PRRT) and impact of selected factors – A single centre cohort study

Introduction: The most common side effect of radioligand therapy is renal damage, early or late. However, limited data exist for the long-term side effects and impact of additional risk factors on renal function in patients treated with PRRT.

Conference:

Presenting Author: Sygula A

Authors: Sygula A, Kropinska A, Kotecka-Blicharz A, Gawlik T, Wycislik M,

Keywords: Neuroendocrine tumour, PRRT, nephrotoxicity, yttrium-90, lutetium-177,

#4132 ACTION-1: A randomised phase Ib/3 trial of RYZ101 compared with standard of care in somatostatin receptor positive, well-differentiated gastroenteropancreatic neuroendocrine tumors with progression following 177Lu somatostatin analogue therapy

Introduction: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are characterized by high-density expression of somatostatin receptors (SSTRs). RYZ101 (225Ac-DOTATATE) is a highly potent alpha-emitting radiopharmaceutical therapy (RPT) being developed for SSTR+ solid tumors. ACTION-1 is a 2-part, global, randomized, controlled, open-label, Phase 1b/3 trial of RYZ101. Part 1 (Phase 1b), an uncontrolled dose de-escalation study, is complete with no dose-limiting toxicities.

Conference:

Presenting Author: Singh S

Authors: Singh S, Tesselaar M, Strosberg J, Jacene H, Halperin D,

Keywords: RYZ101, Gastroenteropancreatic neuroendocrine tumor, Somatostatin receptor, Radiopharmaceutical therapy,

#4110 The role of fibrosis markers in predicting decline in renal function in patients undergoing PRRT

Introduction: Renal impairment due to renal fibrosis is a potential side effect in NET-patients undergoing Peptide Receptor Radionuclide Therapy (PRRT). Fibrosis markers are small collagen formation - and degradation fragments that are measurable in circulation at very early stages of fibrosis formation.

Conference:

Presenting Author: Lau T

Authors: Lau T, Bossen L, Rasmussen D, Karsdal M, Genovese F,

Keywords: PRRT, Biomarker, Fibrosis Marker,

#4042 177Lu-dotatate as salvage therapy in bronchial and GEP NET patients: The IRST "Dino Amadori" experience

Introduction: RLT with SSA represents a treatment of choice after progression from “cold” SSA analogues in NENs. After progression from RLT, other systemic treatments are used including a salvage therapy with RLT that is increasingly proposed.

Conference:

Presenting Author:

Authors: Sansovini M,

Keywords: Neuroendocrine tumor, salvage radioligand therapy,